GLP-1 Agonists in Serious Mental Illness: Current Evidence
In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psychiatric patients from diabetes and obesity before the damage is done? Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 84 GLP-1s in Schizophrenia: Should Semaglutide Be Added for Metabolic Management?
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Psychopharmacology and Psychiatry Updates
EMERGENT-5: Cobenfy and Treatment Durability
Antipsychotics and Weight Gain
EPA vs. DHA: Fish Oil and Treatment-Resistant Depression
AUD Medications and Hepatic Safety
Get summaries like this every morning.
Free AI-powered recaps of Psychopharmacology and Psychiatry Updates and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.